Bafna Pharmaceuticals P/E Ratio
Bafna Pharmaceuticals (BAFNAPH) P/E ratio is not applicable — EPS (TTM) ₹-15.52, 3 consecutive loss quarters. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company has reported losses in the last 3 quarters. P/E ratio is not applicable during loss periods.
Consecutive Loss Quarters: 3
Current EPS: ₹-15.52
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Sept 2019 | -0.25 | -1 | Loss |
| Jun 2019 | -0.90 | -2 | Loss |
| Sept 2018 | -0.80 | -1 | Loss |
Healthcare Peers with Valid P/E Ratios — BAFNAPH Comparison
Healthcare sector average P/E 55.26, median 31.04 — BAFNAPH excluded (negative EPS).
Sector Average PE
55.26
Sector Median PE
31.04
Lowest PE
2.86
Profitable Companies
195
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Sunrest Lifescience | SUNREST | 3.65 | ₹29 | Low |
| Phaarmasia | PHRMASI | 3.84 | ₹68 | Low |
| JFL Life Sciences | JFLLIFE | 4.64 | ₹59 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.69 | ₹7,502 | Low |
| Shelter Pharma | SHELTER | 5.32 | ₹50 | Low |
| Mono Pharmacare | MONOPHARMA | 6.02 | ₹19 | Low |
| Royal Sense | ROYAL | 7.4 | ₹51 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹79 | Low |
| Amwill Health Care | AMWILL | 7.71 | ₹88 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see Bafna Pharmaceuticals share price chart.
- Read Bafna Pharmaceuticals dividend payments for the complete payout history and dividend yield track record.
- See Bafna Pharmaceuticals P/B valuation to compare market price against book value per share.